The effectiveness of 6 versus 12-months of dialectical behaviour therapy for borderline personality disorder: The feasibility of a shorter treatment and evaluating responses (FASTER) trial protocol

Shelley F. McMain, Alexander L. Chapman, Janice R. Kuo, Tim Guimond, David L. Streiner, Katherine L. Dixon-Gordon, Wanrudee Isaranuwatchai, Jeffrey S Hoch

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Although Dialectical Behaviour Therapy (DBT) is an evidence-based psychosocial treatment for borderline personality disorder (BPD), the demand for it exceeds available resources. The commonly researched 12-month version of DBT is lengthy; this can pose a barrier to its adoption in many health care settings. Further, there are no data on the optimal length of psychotherapy for BPD. The aim of this study is to examine the clinical and cost-effectiveness of 6 versus 12 months of DBT for chronically suicidal individuals with BPD. A second aim of this study is to determine which patients are as likely to benefit from shorter treatment as from longer treatment. Methods/Design: Powered for non-inferiority testing, this two-site single-blind trial involves the random assignment of 240 patients diagnosed with BPD to 6 or 12 months of standard DBT. The primary outcome is the frequency of suicidal or non-suicidal self-injurious episodes. Secondary outcomes include healthcare utilization, psychiatric and emotional symptoms, general and social functioning, and health status. Cost-effectiveness outcomes will include the cost of providing each treatment as well as health care and societal costs (e.g., missed work days and lost productivity). Assessments are scheduled at pretreatment and at 3-month intervals until 24 months. Discussion: This is the first study to directly examine the dose-effect of psychotherapy for chronically suicidal individuals diagnosed with BPD. Examining both clinical and cost effectiveness in 6 versus 12 months of DBT will produce answers to the question of how much treatment is good enough. Information from this study will help to guide decisions about the allocation of scarce treatment resources and recommendations about the benefits of briefer treatment.

Original languageEnglish (US)
Article number230
JournalBMC Psychiatry
Volume18
Issue number1
DOIs
StatePublished - Jul 17 2018

Fingerprint

Borderline Personality Disorder
Behavior Therapy
Clinical Protocols
Cost-Benefit Analysis
Psychotherapy
Therapeutics
Delivery of Health Care
Health Care Costs
Health Status
Psychiatry
Costs and Cost Analysis

Keywords

  • Borderline personality disorder
  • Dialectical behaviour therapy
  • Randomized controlled trials
  • Self-injury
  • Suicide

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

The effectiveness of 6 versus 12-months of dialectical behaviour therapy for borderline personality disorder : The feasibility of a shorter treatment and evaluating responses (FASTER) trial protocol. / McMain, Shelley F.; Chapman, Alexander L.; Kuo, Janice R.; Guimond, Tim; Streiner, David L.; Dixon-Gordon, Katherine L.; Isaranuwatchai, Wanrudee; Hoch, Jeffrey S.

In: BMC Psychiatry, Vol. 18, No. 1, 230, 17.07.2018.

Research output: Contribution to journalArticle

McMain, Shelley F. ; Chapman, Alexander L. ; Kuo, Janice R. ; Guimond, Tim ; Streiner, David L. ; Dixon-Gordon, Katherine L. ; Isaranuwatchai, Wanrudee ; Hoch, Jeffrey S. / The effectiveness of 6 versus 12-months of dialectical behaviour therapy for borderline personality disorder : The feasibility of a shorter treatment and evaluating responses (FASTER) trial protocol. In: BMC Psychiatry. 2018 ; Vol. 18, No. 1.
@article{97de56e929c544839bd4f6007ac72a77,
title = "The effectiveness of 6 versus 12-months of dialectical behaviour therapy for borderline personality disorder: The feasibility of a shorter treatment and evaluating responses (FASTER) trial protocol",
abstract = "Background: Although Dialectical Behaviour Therapy (DBT) is an evidence-based psychosocial treatment for borderline personality disorder (BPD), the demand for it exceeds available resources. The commonly researched 12-month version of DBT is lengthy; this can pose a barrier to its adoption in many health care settings. Further, there are no data on the optimal length of psychotherapy for BPD. The aim of this study is to examine the clinical and cost-effectiveness of 6 versus 12 months of DBT for chronically suicidal individuals with BPD. A second aim of this study is to determine which patients are as likely to benefit from shorter treatment as from longer treatment. Methods/Design: Powered for non-inferiority testing, this two-site single-blind trial involves the random assignment of 240 patients diagnosed with BPD to 6 or 12 months of standard DBT. The primary outcome is the frequency of suicidal or non-suicidal self-injurious episodes. Secondary outcomes include healthcare utilization, psychiatric and emotional symptoms, general and social functioning, and health status. Cost-effectiveness outcomes will include the cost of providing each treatment as well as health care and societal costs (e.g., missed work days and lost productivity). Assessments are scheduled at pretreatment and at 3-month intervals until 24 months. Discussion: This is the first study to directly examine the dose-effect of psychotherapy for chronically suicidal individuals diagnosed with BPD. Examining both clinical and cost effectiveness in 6 versus 12 months of DBT will produce answers to the question of how much treatment is good enough. Information from this study will help to guide decisions about the allocation of scarce treatment resources and recommendations about the benefits of briefer treatment.",
keywords = "Borderline personality disorder, Dialectical behaviour therapy, Randomized controlled trials, Self-injury, Suicide",
author = "McMain, {Shelley F.} and Chapman, {Alexander L.} and Kuo, {Janice R.} and Tim Guimond and Streiner, {David L.} and Dixon-Gordon, {Katherine L.} and Wanrudee Isaranuwatchai and Hoch, {Jeffrey S}",
year = "2018",
month = "7",
day = "17",
doi = "10.1186/s12888-018-1802-z",
language = "English (US)",
volume = "18",
journal = "BMC Psychiatry",
issn = "1471-244X",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - The effectiveness of 6 versus 12-months of dialectical behaviour therapy for borderline personality disorder

T2 - The feasibility of a shorter treatment and evaluating responses (FASTER) trial protocol

AU - McMain, Shelley F.

AU - Chapman, Alexander L.

AU - Kuo, Janice R.

AU - Guimond, Tim

AU - Streiner, David L.

AU - Dixon-Gordon, Katherine L.

AU - Isaranuwatchai, Wanrudee

AU - Hoch, Jeffrey S

PY - 2018/7/17

Y1 - 2018/7/17

N2 - Background: Although Dialectical Behaviour Therapy (DBT) is an evidence-based psychosocial treatment for borderline personality disorder (BPD), the demand for it exceeds available resources. The commonly researched 12-month version of DBT is lengthy; this can pose a barrier to its adoption in many health care settings. Further, there are no data on the optimal length of psychotherapy for BPD. The aim of this study is to examine the clinical and cost-effectiveness of 6 versus 12 months of DBT for chronically suicidal individuals with BPD. A second aim of this study is to determine which patients are as likely to benefit from shorter treatment as from longer treatment. Methods/Design: Powered for non-inferiority testing, this two-site single-blind trial involves the random assignment of 240 patients diagnosed with BPD to 6 or 12 months of standard DBT. The primary outcome is the frequency of suicidal or non-suicidal self-injurious episodes. Secondary outcomes include healthcare utilization, psychiatric and emotional symptoms, general and social functioning, and health status. Cost-effectiveness outcomes will include the cost of providing each treatment as well as health care and societal costs (e.g., missed work days and lost productivity). Assessments are scheduled at pretreatment and at 3-month intervals until 24 months. Discussion: This is the first study to directly examine the dose-effect of psychotherapy for chronically suicidal individuals diagnosed with BPD. Examining both clinical and cost effectiveness in 6 versus 12 months of DBT will produce answers to the question of how much treatment is good enough. Information from this study will help to guide decisions about the allocation of scarce treatment resources and recommendations about the benefits of briefer treatment.

AB - Background: Although Dialectical Behaviour Therapy (DBT) is an evidence-based psychosocial treatment for borderline personality disorder (BPD), the demand for it exceeds available resources. The commonly researched 12-month version of DBT is lengthy; this can pose a barrier to its adoption in many health care settings. Further, there are no data on the optimal length of psychotherapy for BPD. The aim of this study is to examine the clinical and cost-effectiveness of 6 versus 12 months of DBT for chronically suicidal individuals with BPD. A second aim of this study is to determine which patients are as likely to benefit from shorter treatment as from longer treatment. Methods/Design: Powered for non-inferiority testing, this two-site single-blind trial involves the random assignment of 240 patients diagnosed with BPD to 6 or 12 months of standard DBT. The primary outcome is the frequency of suicidal or non-suicidal self-injurious episodes. Secondary outcomes include healthcare utilization, psychiatric and emotional symptoms, general and social functioning, and health status. Cost-effectiveness outcomes will include the cost of providing each treatment as well as health care and societal costs (e.g., missed work days and lost productivity). Assessments are scheduled at pretreatment and at 3-month intervals until 24 months. Discussion: This is the first study to directly examine the dose-effect of psychotherapy for chronically suicidal individuals diagnosed with BPD. Examining both clinical and cost effectiveness in 6 versus 12 months of DBT will produce answers to the question of how much treatment is good enough. Information from this study will help to guide decisions about the allocation of scarce treatment resources and recommendations about the benefits of briefer treatment.

KW - Borderline personality disorder

KW - Dialectical behaviour therapy

KW - Randomized controlled trials

KW - Self-injury

KW - Suicide

UR - http://www.scopus.com/inward/record.url?scp=85050090554&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050090554&partnerID=8YFLogxK

U2 - 10.1186/s12888-018-1802-z

DO - 10.1186/s12888-018-1802-z

M3 - Article

C2 - 30016935

AN - SCOPUS:85050090554

VL - 18

JO - BMC Psychiatry

JF - BMC Psychiatry

SN - 1471-244X

IS - 1

M1 - 230

ER -